Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Fujian Shengdi Pharmaceutical: HRS9531 (Subsidiary of Jiangsu Hengrui Pharmaceutical) [59] [59] In a phase 1 study evaluating an oral GLP1R/GIP dual agonist, participants received subcutaneous injections of 8.1mg
GLP1 RA lower blood glucose by multiple actions including promoting insulin release, reducing glucagon secretion and delaying gastric emptying
CV=cardiovascular
It acts on three receptors simultaneously: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Other FDA-approved weight management medications provide alternatives worth considering
Research shows that continuing therapy produces more stable results than stopping, as weight regain often occurs when the medication is discontinued
US$ 27.06
US$ 22.90
US$ 28.89
